BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18327303)

  • 1. Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome.
    Mrówka P; Głodkowska E; Młynarczuk-Biały I; Biały L; Kuckelkorn U; Nowis D; Makowski M; Legat M; Gołab J
    Acta Biochim Pol; 2008; 55(1):75-84. PubMed ID: 18327303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway.
    Hung SH; Yeh CH; Huang HT; Wu P; Ho ML; Chen CH; Wang C; Chao D; Wang GJ
    Life Sci; 2008 Mar; 82(11-12):561-9. PubMed ID: 18272184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
    Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
    Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats.
    Lahiri S; Sen T; Palit G
    Eur J Pharmacol; 2009 May; 609(1-3):118-25. PubMed ID: 19281808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer.
    Shigeto T; Yokoyama Y; Xin B; Mizunuma H
    Oncol Rep; 2007 Oct; 18(4):833-40. PubMed ID: 17786343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors induce peroxisome proliferator-activated receptor transactivation through RXR accumulation and a protein kinase C-dependent pathway.
    Tsao WC; Wu HM; Chi KH; Chang YH; Lin WW
    Exp Cell Res; 2005 Mar; 304(1):234-43. PubMed ID: 15707588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
    Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
    Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells.
    Saiki M; Hatta Y; Yamazaki T; Itoh T; Enomoto Y; Takeuchi J; Sawada U; Aizawa S; Horie T
    Int J Oncol; 2006 Aug; 29(2):437-43. PubMed ID: 16820887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone inhibits homocysteine-induced migration of vascular smooth muscle cells through a peroxisome proliferator-activated receptor gamma-independent mechanism.
    Li L; Gao PJ; Xi R; Wu CF; Zhu DL; Yan J; Lu GP
    Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1471-6. PubMed ID: 18759864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
    Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
    Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
    Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
    Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells.
    Bernardo A; Bianchi D; Magnaghi V; Minghetti L
    J Neuropathol Exp Neurol; 2009 Jul; 68(7):797-808. PubMed ID: 19535992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor-gamma ligands 15-deoxy-delta(12,14)-prostaglandin J2 and pioglitazone inhibit hydroxyl peroxide-induced TNF-alpha and lipopolysaccharide-induced CXC chemokine expression in neonatal rat cardiac myocytes.
    Liu J; Xia Q; Zhang Q; Li H; Zhang J; Li A; Xiu R
    Shock; 2009 Sep; 32(3):317-24. PubMed ID: 19174742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
    Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
    Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of small-molecule cyclin D1-ablative agents.
    Huang JW; Shiau CW; Yang J; Wang DS; Chiu HC; Chen CY; Chen CS
    J Med Chem; 2006 Jul; 49(15):4684-9. PubMed ID: 16854074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of peroxisome proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats.
    Yamamoto Y; Ono T; Dhar DK; Yamanoi A; Tachibana M; Tanaka T; Nagasue N
    J Gastroenterol Hepatol; 2008 Jun; 23(6):930-7. PubMed ID: 18565023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner.
    Bonofiglio D; Qi H; Gabriele S; Catalano S; Aquila S; Belmonte M; Andò S
    Endocr Relat Cancer; 2008 Jun; 15(2):545-57. PubMed ID: 18509005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro.
    Gruszka A; Kunert-Radek J; Pawlikowski M
    Neuro Endocrinol Lett; 2005 Feb; 26(1):51-4. PubMed ID: 15726020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone promotes preadipocyte proliferation by downregulating p16(Ink4a).
    Hasan AU; Ohmori K; Hashimoto T; Kamitori K; Hirata Y; Ishihara Y; Okamoto N; Noma T; Kosaka H; Tokuda M; Kohno M
    Biochem Biophys Res Commun; 2011 Jul; 411(2):375-80. PubMed ID: 21741366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis.
    Aljada A; O'Connor L; Fu YY; Mousa SA
    Angiogenesis; 2008; 11(4):361-7. PubMed ID: 18810647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.